Structure-based design and protein X-ray analysis of a protein kinase inhibitor.
Furet, P., Meyer, T., Strauss, A., Raccuglia, S., Rondeau, J.M.(2002) Bioorg Med Chem Lett 12: 221-224
- PubMed: 11755359 
- DOI: https://doi.org/10.1016/s0960-894x(01)00715-6
- Primary Citation of Related Structures:  
1JVP - PubMed Abstract: 
A 5-aryl-1H-pyrazole molecular scaffold was designed to ligate the ATP binding site of cyclin dependent kinase 2 (CDK2) on the basis of crystallographic information. A search of the compound collection of Novartis using this scaffold as substructure query led to the identification of PKF049-365 as a representative of a new class of inhibitors of the cell cycle kinases CDK1/2. The three-dimensional structure of CDK2 in complex with PKF049-365 was subsequently determined by protein crystallography and refined to 1.53 A resolution. The X-ray analysis confirmed the binding mode expected from the design hypothesis. In addition, it revealed an alternative binding orientation involving a second tautomeric form of the inhibitor that was not envisaged during the design stage.
Organizational Affiliation: 
Novartis Pharmaceuticals Inc., Oncology Research, CH-4002 Basel, Switzerland. pascal.furet@pharma.novartis.com